Gilde Healthcare participates in EUR 36.6M financing round of cardiovascular company Sanifit

Utrecht, The Netherlands and Palma de Mallorca, Spain – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company, today announces that it has raised €36.6M in a late stage Series C financing round. The company is focused on the development of SNF472, a promising drug for the treatment of cardiovascular diseases linked to calcification in patients with End Stage Renal Disease (ESRD) undergoing haemodialysis.
Gilde Healthcare invested alongside a syndicate of international investors.

With the proceeds from this financing round Sanifit will advance its lead drug candidate through phase IIb as a treatment for cardiovascular diseases linked to calcification and through phase II/III for calciphylaxis. SNF472 has shown significant efficacy data in more than 20 preclinical studies and excellent safety and tolerability data in a phase Ia clinical trial in healthy volunteers. SNF472 is currently concluding a phase Ib/IIa pharmacology study in haemodialysis patients.

ESRD patients treated with dialysis experience higher rates of serious cardiovascular adverse events  and  mortality  as  a  consequence  of  accelerated  progression  of  cardiovascular calcification. Half of the mortality in dialysis patients is from cardiovascular complications. Calciphylaxis is the most severe form of cardiovascular calcification. It is a devastating rare disease that affects up to 4% of dialysis patients and has an overall mortality rate of about 80%. There are approximately 2.5 million dialysis patients worldwide with no effective treatment for this medical condition. ESRD represents a market opportunity of over €2Bn.

About Gilde Healthcare

Gilde Healthcare (Utrecht, The Netherlands and Cambridge, Massachusetts, US) is a European fund manager specialized in fast growing private healthcare companies. Since 2001 Gilde Healthcare raised EUR 600M in dedicated funds across two business lines: Healthcare Technologies and Healthcare Services. The Gilde Healthcare Technology funds invest growth and later-stage capital in businesses active in digital health, medical technologies and therapeutics, both in Europe and the US. The Gilde Healthcare Services funds participate in lower mid-market service providers in the Benelux and Germany. For more information please visit www.gildehealthcare.com